{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:08:04Z","timestamp":1793941684769,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Caspase-2 (Casp2) is a promising therapeutic target in several human diseases, including nonalcoholic steatohepatitis (NASH) and Alzheimer\u2019s disease (AD). However, the design of an active-site-directed inhibitor selective to individual caspase family members is challenging because caspases have extremely similar active sites. Here we present new peptidomimetics derived from the VDVAD pentapeptide structure, harboring non-natural modifications at the P2 position and an irreversible warhead. Enzyme kinetics show that these new compounds, such as LJ2 or its specific isomers LJ2a, and LJ3a, strongly and irreversibly inhibit Casp2 with genuine selectivity. In agreement with the established role of Casp2 in cellular stress responses, LJ2 inhibits cell death induced by microtubule destabilization or hydroxamic acid-based deacetylase inhibition. The most potent peptidomimetic, LJ2a, inhibits human Casp2 with a remarkably high inactivation rate (\n                    <jats:italic>k<\/jats:italic>\n                    <jats:sub>3<\/jats:sub>\n                    \/\n                    <jats:italic>K<\/jats:italic>\n                    <jats:sub>i<\/jats:sub>\n                    ~5,500,000\u2009M\n                    <jats:sup>\u22121<\/jats:sup>\n                    \u2009s\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>1<\/jats:sup>\n                    ), and the most selective inhibitor, LJ3a, has close to a 1000 times higher inactivation rate on Casp2 as compared to Casp3. Structural analysis of LJ3a shows that the spatial configuration of C\n                    <jats:sub>\u03b1<\/jats:sub>\n                    at the P2 position determines inhibitor efficacy. In transfected human cell lines overexpressing site-1 protease (S1P), sterol regulatory element-binding protein 2 (SREBP2) and Casp2, LJ2a and LJ3a fully inhibit Casp2-mediated S1P cleavage and thus SREBP2 activation, suggesting a potential to prevent NASH development. Furthermore, in primary hippocampal neurons treated with \u03b2-amyloid oligomers, submicromolar concentrations of LJ2a and of LJ3a prevent synapse loss, indicating a potential for further investigations in AD treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41419-022-05396-2","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T10:09:59Z","timestamp":1668506999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Genuine selective caspase-2 inhibition with new irreversible small peptidomimetics"],"prefix":"10.1038","volume":"13","author":[{"given":"Elodie","family":"Bosc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Anastasie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feryel","family":"Soualmia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8484-1381","authenticated-orcid":false,"given":"Pascale","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gullen","family":"Lacin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-5263","authenticated-orcid":false,"given":"Kaitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Duplus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Tixador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Sproul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Brugg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Reboud-Ravaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1312-7441","authenticated-orcid":false,"given":"Carol M.","family":"Troy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Shelanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Bouaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chahrazade","family":"El Amri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5301-1569","authenticated-orcid":false,"given":"Etienne D.","family":"Jacotot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"5396_CR1","unstructured":"Rawlings ND & Salvesen G (eds). Handbook of proteolytic enzymes. 3rd edn. (Elsevier, London, 2013), Vol. 2 (chap. 505\u2013513): 2237\u201385."},{"key":"5396_CR2","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.immuni.2019.05.020","volume":"50","author":"N Van Opdenbosch","year":"2019","unstructured":"Van Opdenbosch N, Lamkanfi M. Caspases in cell death, inflammation, and disease. Immunity. 2019;50:1352\u201364.","journal-title":"Immunity"},{"key":"5396_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/cdd.2014.216","volume":"22","author":"S Shalini","year":"2015","unstructured":"Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ. 2015;22:526\u201339.","journal-title":"Cell Death Differ"},{"key":"5396_CR4","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2174\/156802605775009720","volume":"5","author":"SD Linton","year":"2005","unstructured":"Linton SD. Caspase inhibitors: a pharmaceutical industry perspective. Curr Top Med Chem. 2005;5:1697\u2013717.","journal-title":"Curr Top Med Chem"},{"key":"5396_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04240-3","volume":"12","author":"S Dhani","year":"2021","unstructured":"Dhani S, Zhao Y, Zhivotovsky B. A long way to go: caspase inhibitors in clinical use. Cell Death Dis. 2021;12:949.","journal-title":"Cell Death Dis"},{"key":"5396_CR6","doi-asserted-by":"publisher","first-page":"21777","DOI":"10.1074\/jbc.R800084200","volume":"284","author":"C Pop","year":"2009","unstructured":"Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem. 2009;284:21777\u201381.","journal-title":"J Biol Chem"},{"key":"5396_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/bs.ircmb.2016.12.002","volume":"332","author":"MA Miles","year":"2017","unstructured":"Miles MA, Kitevska-Ilioski T, Hawkins CJ. Old and novel functions of caspase-2. Int Rev Cell Mol Biol. 2017;332:155\u2013212.","journal-title":"Int Rev Cell Mol Biol"},{"key":"5396_CR8","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/cells9051259","volume":"9","author":"V Vigneswara","year":"2020","unstructured":"Vigneswara V, Ahmed Z. The role of caspase-2 in regulating cell fate. Cells. 2020;9:1259.","journal-title":"Cells"},{"key":"5396_CR9","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1101\/gad.12.9.1304","volume":"12","author":"L Bergeron","year":"1998","unstructured":"Bergeron L, Perez GI, Macdonald G, Shi L, Sun Y, Jurisicova A, et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev. 1998;12:1304\u201314.","journal-title":"Genes Dev"},{"key":"5396_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.molcel.2009.07.023","volume":"35","author":"L Bouchier-Hayes","year":"2009","unstructured":"Bouchier-Hayes L, Oberst A, McStay GP, Connell S, Tait SW, Dillon CP, et al. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell. 2009;35:830\u201340.","journal-title":"Mol Cell"},{"key":"5396_CR11","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1136\/gutjnl-2014-307362","volume":"64","author":"MV Machado","year":"2015","unstructured":"Machado MV, Michelotti GA, Pereira Tde A, Boursier J, Kruger L, Swiderska-Syn M, et al. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut. 2015;64:1148\u201357.","journal-title":"Gut"},{"key":"5396_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cell.2018.08.020","volume":"175","author":"JY Kim","year":"2018","unstructured":"Kim JY, Garcia-Carbonell R, Yamachika S, Zhao P, Dhar D, Loomba R, et al. ER stress drives lipogenesis and steatohepatitis via caspase-2 activation of S1P. Cell. 2018;175:133\u201345.","journal-title":"Cell"},{"key":"5396_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11575-1","volume":"10","author":"ZX Xu","year":"2019","unstructured":"Xu ZX, Tan JW, Xu H, Hill CJ, Ostrovskaya O, Martemyanov KA, et al. Caspase-2 promotes AMPA receptor internalization and cognitive flexibility via mTORC2-AKT-GSK3\u03b2 signaling. Nat Commun. 2019;10:3622.","journal-title":"Nat Commun"},{"key":"5396_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ana.22431","volume":"70","author":"Y Carlsson","year":"2011","unstructured":"Carlsson Y, Schwendimann L, Vontell R, Rousset CI, Wang X, Lebon S, et al. Genetic inhibition of caspase-2 reduces hypoxic-ischemic and excitotoxic neonatal brain injury. Ann Neurol. 2011;70:781\u20139.","journal-title":"Ann Neurol"},{"key":"5396_CR15","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1038\/cddis.2011.54","volume":"2","author":"Z Ahmed","year":"2011","unstructured":"Ahmed Z, Kalinski H, Berry M, Almasieh M, Ashush H, Slager N, et al. Ocular neuroprotection by siRNA targeting Caspase-2. Cell Death Disease. 2011;2:e173.","journal-title":"Cell Death Disease"},{"key":"5396_CR16","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1523\/JNEUROSCI.20-04-01386.2000","volume":"20","author":"CM Troy","year":"2000","unstructured":"Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci. 2000;20:1386\u201392.","journal-title":"J Neurosci"},{"key":"5396_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2927","volume":"4","author":"J Pozueta","year":"2013","unstructured":"Pozueta J, Lefort R, Ribe EM, Troy CM, Arancio O, Shelanski ML. Caspase-2 is required for dendritic spine and behavioural alterations in J20 APP transgenic mice. Nat Commun. 2013;4:1939.","journal-title":"Nat Commun"},{"key":"5396_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/nm.4199","volume":"22","author":"X Zhao","year":"2016","unstructured":"Zhao X, Kotilinek LA, Smith B, Hlynialuk C, Zahs K, Ramsden M, et al. Caspase-2 cleavage of tau reversibly impairs memory. Nat Med. 2016;22:1268\u201376.","journal-title":"Nat Med"},{"key":"5396_CR19","doi-asserted-by":"publisher","first-page":"12546","DOI":"10.1021\/acs.chemrev.5b00434","volume":"115","author":"M Poreba","year":"2015","unstructured":"Poreba M, Szalek A, Kasperkiewicz P, Rut W, Salvesen GS, Drag M. Small molecule active site directed tools for studying human caspases. Chem Rev. 2015;115:12546\u2013629.","journal-title":"Chem Rev"},{"key":"5396_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/sj.cdd.4402044","volume":"14","author":"D Chauvier","year":"2007","unstructured":"Chauvier D, Ankri S, Charriaut-Marlangue C, Casimir R, Jacotot E. Broad-spectrum caspase inhibitors: from myth to reality? Cell Death Differ. 2007;14:387\u201391.","journal-title":"Cell Death Differ"},{"key":"5396_CR21","doi-asserted-by":"crossref","unstructured":"Wannamaker W, Davies R, Namchuk M, Pollard J, Ford P, Ku G, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme\/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007;321:509\u201316..","DOI":"10.1124\/jpet.106.111344"},{"key":"5396_CR22","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1021\/jm050307e","volume":"48","author":"SD Linton","year":"2005","unstructured":"Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, et al. First-in-class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem. 2005;48:6779\u201382.","journal-title":"J Med Chem"},{"key":"5396_CR23","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1021\/acs.jmedchem.1c00172","volume":"64","author":"HR Kim","year":"2021","unstructured":"Kim HR, Tagirasa R, Yoo E. Covalent small molecule immunomodulators targeting the protease active site. J Med Chem. 2021;64:5291\u2013322.","journal-title":"J Med Chem"},{"key":"5396_CR24","doi-asserted-by":"publisher","first-page":"a008680","DOI":"10.1101\/cshperspect.a008680","volume":"5","author":"M Poreba","year":"2013","unstructured":"Poreba M, Str\u00f3zyk A, Salvesen GS, Drag M. Caspase substrates and inhibitors. Cold Spring Harb Perspect Biol. 2013;5:a008680.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5396_CR25","doi-asserted-by":"publisher","first-page":"42441","DOI":"10.1074\/jbc.M304895200","volume":"278","author":"A Schweizer","year":"2003","unstructured":"Schweizer A, Briand C, Grutter MG. Crystal structure of caspase-2, apical initiator of the intrinsic apoptotic pathway. J Biol Chem. 2003;278:42441\u20137.","journal-title":"J Biol Chem"},{"key":"5396_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jmb.2006.05.041","volume":"360","author":"B Fang","year":"2006","unstructured":"Fang B, Boross PI, Tozser J, Weber IT. Structural and kinetic analysis of caspase-3 reveals role for S5 binding site in substrate recognition. J Mol Biol. 2006;360:654\u201366.","journal-title":"J Mol Biol"},{"key":"5396_CR27","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1074\/jbc.272.15.9677","volume":"272","author":"RV Talanian","year":"1997","unstructured":"Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, et al. Substrate specificities of caspase family proteases. J Biol Chem. 1997;272:9677\u201382.","journal-title":"J Biol Chem"},{"key":"5396_CR28","doi-asserted-by":"publisher","first-page":"17907","DOI":"10.1074\/jbc.272.29.17907","volume":"272","author":"NA Thornberry","year":"1997","unstructured":"Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, et al. A combinatorial approach defines specificities of members of the caspase family and Granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem. 1997;272:17907\u201311.","journal-title":"J Biol Chem"},{"key":"5396_CR29","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1038\/sj.onc.1207107","volume":"22","author":"A Degterev","year":"2003","unstructured":"Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543\u201367.","journal-title":"Oncogene"},{"key":"5396_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.cdd.4402260","volume":"15","author":"GP McStay","year":"2008","unstructured":"McStay GP, Salvesen GS, Green DR. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 2008;15:322\u201331.","journal-title":"Cell Death Differ"},{"key":"5396_CR31","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1038\/cddis.2011.87","volume":"2","author":"D Chauvier","year":"2011","unstructured":"Chauvier D, Renolleau S, Holifanjaniaina S, Ankri S, Bezault M, Schwendimann L, et al. Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor. Cell Death Disease. 2011;2:e203.","journal-title":"Cell Death Disease"},{"key":"5396_CR32","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1016\/j.bmc.2011.08.020","volume":"19","author":"MC Maillard","year":"2011","unstructured":"Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, et al. Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors. Bioorg Med Chem. 2011;19:5833\u201351.","journal-title":"Bioorg Med Chem"},{"key":"5396_CR33","first-page":"54 ECDO81","volume":"5","author":"E Bosc","year":"2019","unstructured":"Bosc E, Anastasie J, Soulami F, Pretat S, Lacin G, Duplus E, et al. Selective caspase-2 inhibition and synapse protection with a new irreversible pentapeptide derivative. Abstract of 26th Conference of the European Cell Death Organization (ECDO 2018). Cell Death Discov. 2019;5:54 ECDO81.","journal-title":"Cell Death Discov"},{"key":"5396_CR34","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1038\/s41418-019-0329-2","volume":"26","author":"M Poreba","year":"2019","unstructured":"Poreba M, Rut W, Grobortz K, Snipas SJ, Salvesen GS, Drag M. Potent and selective caspase-2 inhibitor prevents MDM-2 cleavage in reversine-treated colon cancer cells. Cell Death Diff. 2019;26:2695\u2013709.","journal-title":"Cell Death Diff"},{"key":"5396_CR35","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1021\/jm990070k","volume":"42","author":"C Doucet","year":"1999","unstructured":"Doucet C, Pochet L, Thierry N, Pirotte B, Delarge J, Reboud-Ravaux M. 6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase. J Med Chem. 1999;42:4161\u201371.","journal-title":"J Med Chem"},{"key":"5396_CR36","doi-asserted-by":"publisher","first-page":"11612","DOI":"10.1074\/jbc.M210207200","volume":"278","author":"WB Stine","year":"2003","unstructured":"Stine WB, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612\u201322.","journal-title":"J Biol Chem"},{"key":"5396_CR37","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1096\/fj.13-229781","volume":"27","author":"S Magnifico","year":"2013","unstructured":"Magnifico S, Saias L, Deleglise B, Duplus E, Kilinc D, Miquel MC, et al. NAD+ acts on mitochondrial SirT3 to prevent axonal caspase activation and axonal degeneration. FASEB J. 2013;27:4712\u201322.","journal-title":"FASEB J"},{"key":"5396_CR38","doi-asserted-by":"publisher","first-page":"e71103","DOI":"10.1371\/journal.pone.0071103","volume":"8","author":"B Deleglise","year":"2013","unstructured":"Deleglise B, Lassus B, Soubeyre V, Alleaume-Butaux A, Hjorth JJ, Vignes M, et al. Synapto-protective drugs evaluation in reconstructed neuronal network. PLoS ONE. 2013;8:e71103.","journal-title":"PLoS ONE"},{"key":"5396_CR39","first-page":"145","volume":"2","author":"B Deleglise","year":"2014","unstructured":"Deleglise B, Magnifico S, Duplus E, Vaur P, Soubeyre V, Belle M, et al. \u03b2-amyloid induces a dying-back process and remote trans-synaptic alterations in a microfluidic-based reconstructed neuronal network. Acta Neuropathol Commun. 2014;2:145.","journal-title":"Acta Neuropathol Commun"},{"key":"5396_CR40","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1038\/sj.onc.1211005","volume":"27","author":"LH Ho","year":"2008","unstructured":"Ho LH, Read SH, Dorstyn L, Lambrusco L, Kumar S. Caspase-2 is required for cell death induced by cytoskeletal disruption. Oncogene. 2008;27:3393\u2013404.","journal-title":"Oncogene"},{"key":"5396_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/leu.2010.315","volume":"25","author":"H Hasegawa","year":"2011","unstructured":"Hasegawa H, Yamada Y, Tsukasaki K, Mori N, Tsuruda K, Sasaki D, et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia\/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia. 2011;25:575\u201387.","journal-title":"Leukemia"},{"key":"5396_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molcel.2011.06.012","volume":"43","author":"TG Oliver","year":"2011","unstructured":"Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, et al. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell. 2011;43:57\u201371.","journal-title":"Mol Cell"},{"key":"5396_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1101\/gad.289728.116","volume":"31","author":"LL Fava","year":"2017","unstructured":"Fava LL, Schuler F, Sladky V, Haschka MD, Soratroi C, Eiterer L, et al. The PIDDosome activates p53 in response to supernumerary centrosomes. Genes Dev. 2017;31:34\u201345.","journal-title":"Genes Dev"},{"key":"5396_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cmet.2022.08.005","volume":"34","author":"JY Kim","year":"2022","unstructured":"Kim JY, Wang LQ, Sladky VC, Oh TG, Liu J, Trinh K, et al. PIDDosome-SCAP crosstalk controls high-fructose-diet-dependent transition from simple steatosis to steatohepatitis. Cell Metab. 2022;34:1\u201313.","journal-title":"Cell Metab"},{"key":"5396_CR45","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41418-020-0556-6","volume":"27","author":"VC Sladky","year":"2020","unstructured":"Sladky VC, Villunger A. Uncovering the PIDDosome and caspase-2 as regulators of organogenesis and cellular differentiation. Cell Death Differ. 2020;27:2037\u201347.","journal-title":"Cell Death Differ"},{"key":"5396_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5396_CR47","doi-asserted-by":"crossref","first-page":"e12179","DOI":"10.1002\/trc2.12179","volume":"7","author":"J Cummings","year":"2021","unstructured":"Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer\u2019s disease drug development pipeline: 2021. Alzheimer\u2019s Dement (NY). 2021;7:e12179.","journal-title":"Alzheimer\u2019s Dement (NY)"},{"key":"5396_CR48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","volume":"72","author":"G Garcia-Tsao","year":"2020","unstructured":"Garcia-Tsao G, Bosch J, Kayali Z, Harrison SA, Abdelmalek MF, Lawitz E, et al. Randomized placebo-controlled trial of emricasan in non-alcoholic steatohepatitis (NASH) cirrhosis with severe portal hypertension. J Hepatol. 2020;72:885\u201395.","journal-title":"J Hepatol"},{"key":"5396_CR49","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Goodman Z, Jabbar A, Vemulapalli R, Younes ZH, Freilich B, et al. A randomized, placebo-controlled trial of Emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020;72:816\u201327.","journal-title":"J Hepatol"},{"key":"5396_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.19","volume":"7","author":"MV Machado","year":"2016","unstructured":"Machado MV, Michelotti GA, Jewell ML, Pereira TA, Xie G, Premont RT, et al. Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease. Cell Death Dis. 2016;7:e2096.","journal-title":"Cell Death Dis"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05396-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T16:35:45Z","timestamp":1701362145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05396-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["5396"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05396-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.13.472505","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.J. is the inventor of a patent titled \u201cNovel derivatives and their use as selective inhibitors of Caspase-2\u201d (WO\/2017\/162674). E.J. and E.B. are inventors of a patent titled \u201cNovel compounds and their use as selective inhibitors of Caspase-2\u201d WO\/2019\/068538. M.K. and J.Y.K. hold a patent on mouse models for the treatment of NASH, M.K. is a founder of Elgia Pharmaceuticals and has received research support from Jansen and Gossamer Bio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"959"}}